Differential WNT Activity in Colorectal Cancer Confers Limited Tumorigenic Potential and Is Regulated by MAPK Signaling

David Horst1,3, Justina Chen1, Teppei Morikawa1, Shuji Ogino1,2, Thomas Kirchner3, and Ramesh A. Shivdasani1

Abstract

Colorectal cancers (CRC) express the WNT effector protein β-catenin in a heterogeneous subcellular pattern rather than uniformly in the nucleus. In this study, we investigated this important aspect of molecular heterogeneity in CRCs by analyzing its basis and relationship with tumor-initiating capability. CRC cells with the highest WNT levels showed only a marginal increase in tumor initiation capacity. Notably, high WNT activity correlated with a coincident activation of robust mitogen-activated protein kinase (MAPK) signaling, which when upregulated by KRAS expression or downregulated by epidermal growth factor receptor inhibition elicited parallel effects on WNT activity. These findings suggested that on its own high WNT activity may not be a reliable signifier of tumor-initiating potential or stem-like potential. Furthermore, they suggest that MAPK signaling is a critical modifier of intratumoral heterogeneity that contributes significantly to determining the impact of WNT activity on stemness phenotypes in colon cancer cells. Cancer Res; 72(6); 1–10. ©2012 AACR.

Introduction

Colorectal cancer (CRC) derives from normal colonic mucosa by stepwise accumulation of somatic genetic alterations, starting with inactivation of the tumor suppressor gene Adenomatous Polyposis Coli (APC) or activation of the oncogene β-catenin (CTNNB1; ref. 1). Among additional mutations identified frequently in human CRC are those in the KRAS oncogene, which occur in more than 40% of cases (2) and activate signaling through the mitogen-activated protein kinase (MAPK) pathway. APC is a negative regulator of WNT signaling and its mutational inactivation leads to accumulation of β-catenin, which associates with transcription factors of the T-cell factor (TCF) family to activate WNT target genes (3). Although this understanding implies that the WNT pathway is uniformly active in all tumor cells that carry mutant APC or CTNNB1, colon cancers show substantial heterogeneity in the accumulation of nuclear β-catenin, which is evident in about 60% of resected tumor specimens, often at the invasive front (4, 5). Such differential accumulation suggests that, in addition to APC and CTNNB1 mutations, other pathway alterations or stimulatory factors external to tumor cells influence β-catenin distribution and WNT pathway activity in CRC (6, 7). For example, CpG island hypermethylation is inversely associated with β-catenin activation (8) and APC mutation (9), as well as amplification of the CDK8 locus, which encodes a member of the mediator complex, contributes to β-catenin-driven cell transformation (10).

Like other solid tumors, CRCs contain a subpopulation of cells that differ from the majority of tumor cells in displaying an enhanced potential to establish tumors in immune compromised mice; these are thought to represent the clonogenic tumor-initiating cells (11–13). Because some surface markers that have been used to enrich tumor-initiating cells, including CD133 and CD44, are proposed targets of WNT signaling (14, 15), one possibility is that cells showing nuclear β-catenin may harbor the highest tumorigenic potential. In support of this idea, a recent report showed that cell populations isolated from CRCs on the basis of high activity of a lentiviral WNT pathway reporter were more tumorigenic than cells with low or absent reporter activity (16). By contrast, we report here that our independent investigation of differential WNT activity in CRC cell lines and primary CRC xenografts revealed poor correlation between increased WNT activity and the potential to initiate tumors. In examining correlates of WNT signaling heterogeneity, we further found that nuclear β-catenin accumulated most in cells with active MAPK signaling and that nuclear β-catenin correlated with KRAS mutation in a large collection of surgical CRC cases. Moreover, gain- and loss-of-function

Authors’ Affiliations: 1Department of Medical Oncology, Dana-Farber Cancer Institute and Departments of Medicine, and 2Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; and 3Pathologisches Institut der Ludwig-Maximilians-Universit"at M"unchen, Germany.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Authors: David Horst, Pathologisches Institut der LMU, ThalkirchnerStr.36, 80337 M"unchen, Germany. Phone: 49-89-2180-73611; Fax: 49-89-2180-73671; E-mail: david.horst@med.uni-muenchen.de; and Ramesh A. Shivdasani, Dana-Farber Cancer Institute, 450 Brookline Avenue Boston, MA 02215. Phone: 1-617-632-5746; Fax: 1-617-582-7198; E-mail: ramesh_shivdasani@dfci.harvard.edu

doi: 10.1158/0008-5472.CAN-11-3222

©2012 American Association for Cancer Research.
studies revealed regulation of differential WNT activity by MAPK signaling. Thus, common mutations that activate MAPK signaling through the KRAS oncogene may be especially important in CRC, in part, by virtue of their effects on WNT pathway activity. One important feature of our study is the use of both cell lines and primary human CRCs, which may model tumor properties more accurately than do CRC cell lines alone.

Materials and Methods

Cloning of lentiviral vectors

All template plasmids were obtained through Addgene (www.addgene.org). TOP-GFP was constructed by replacing the PGK promoter in the lentiviral vector pRRLSIN.cPPT.PGK-GFP. WPRE (constructed in Didier Trono’s lab) with a 7xTCF/LEF optimal promoter cassette (7xTOP) from the M50 Super TOPFlash plasmid (17). To construct the double color vector TOP-GFP.mC, we inserted 4 additional TCF/LEF binding sites (GATCAAAGG) into a lentiviral TOP-dGFP reporter containing 3 such binding sites (18), yielding 7xTOP-dGFP. We then amplified this cassette using PCR and inserted it into the HpaI site of lentiviral PGK-H2B-BmCherry (19). To achieve destabilized dGFP into enhanced eGFP, we used site-directed mutagenesis (Stratagene) to insert a stop codon between GFP and the attached ornithine decarboxylase sequence, yielding lentiviral TOP-GFP.mC. To construct the control vectors FOP-GFP and FOP-GFP.mC, we replaced 7xTOP cassettes with synthetic 7xFOP cassettes (IDT-DNA), which carry mutated TCF/LEF binding sites (GgcCAAAGG). A mutant KRAS-expressing lentiviral vector UG2K was constructed by inserting KRAS\textsubscript{G12V} from the pBabe K-Ras12V plasmid (20) into a pUltra lentiviral backbone (constructed in Malcolm Moore’s lab) to yield lentiviral TOP-GFP.mC. Modified vector elements were verified by restriction analysis and sequencing. Tissue culture, lentivirus production, transduction, and immunoblotting

Caco2 and HEK293T cells were purchased from the American Type Culture Collection. SW1222 cells were obtained from the Ludwig Institute for Cancer Research (New York). Cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco) supplemented with 10% FBS, 1% glutamine, and 1x penicillin–streptomycin. HEK293T cells, plated in 10-cm dishes, were cotransfected with 10 μg lentiviral vector, 10 μg pCMV-dR8.91, and 2 μg pMD2.G (21) in the presence of 60 μl Lipofectamine 293 (Invitrogen). Medium was replaced after 12 hours with DMEM containing 30% FBS and 36 hours later, conditioned medium was passed through 0.45-μm filters (Millipore), mixed 1:1 with DMEM, and used to infect cultured CRC cell lines or disaggregated primary colon cancer cells in the presence of 8 μg/mL polybrene (Sigma-Aldrich). Transduced tumor cells were washed in PBS and transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. For comparative experiments, GFP\textsuperscript{HIGH} and GFP\textsuperscript{LOW} tumor cell subpopulations were injected into opposing flanks of the same mouse. Animals were monitored weekly and tumors were measured using calipers. Mice were sacrificed when tumors reached a size of 1.5 cm or in the event of earlier illness. In some experiments, 0.2 mg cetuximab (Bristol-Meyers Squibb) or PBS (control) was injected into the peritoneum of tumor-bearing mice every other day, starting after subcutaneous tumors exceeded more than 0.5 cm; CTNNB1 staining was analyzed after 10 days of cetuximab treatment.

Gene expression analyses

RNA was isolated from flow-sorted GFP\textsuperscript{HIGH} and GFP\textsuperscript{LOW} tumor cells using TRIzol Reagent (Invitrogen), treated with DNase, and first strand cDNA was synthesized using a QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-time PCR applied 40 cycles of amplification at 95°C (15 seconds) and 60°C (1 minute) using Sybr green (Roche), a 7500 instrument (Applied Biosystems), and the primers listed in Supplementary Table S1. Real-time reverse transcriptase PCR (RT-PCR) results were first normalized to \textit{Gapdh} mRNA levels in the same sample and then to levels of the corresponding transcript in GFP\textsuperscript{LOW} tumor cells.
Histology and immunohistochemistry

Tumor tissues were fixed in 4% paraformaldehyde, dehydrated in ethanol and xylene, and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E). For immunohistochemistry, antigens were retrieved in 10 mmol/L Na citrate, pH 6, for 10 minutes in a pressure cooker (Biocare Medical). Slides were blocked with 0.5% hydrogen peroxide in methanol for 20 minutes, followed by 5% FBS in PBS for 30 minutes. Slides were incubated first with mouse β-catenin (BD Transduction Laboratories; 1:250), mouse active–β-Catenin (1:100; Millipore), rabbit GFP (1:250; Cell Signaling), or rabbit phospho-p44/42 MAPK Ab (1:250; Cell Signaling) overnight at 4°C, washed with PBS, and then with biotinylated goat anti-mouse or anti-rabbit Ab (1:300; Vector Laboratories) for 1 hour at room temperature. Staining was detected using the Vectastain Elite ABC Kit (Vector) and diaminobenzidine as the substrate. For single staining, slides were counterstained with hematoxylin. For double staining, dephospho–β-catenin stained slides were incubated with rabbit GFP Ab (1:250; Cell Signaling) for 1 hour and developed with a MACH 3 Rabbit AP-Polymer Kit (Biocare medical) and Permanent Red (Dako). For p-ERK/β-catenin and GFP/β-catenin double staining, slides were incubated first with rabbit GFP or phospho-p44/42 MAPK Ab (1:250; Cell Signaling) for 1 hour at room temperature, washed in PBS, and then with goat anti-rabbit Alexa Fluor 488– or Alexa Fluor 546–conjugated secondary Ab (1:500; Invitrogen). Fluorescence images were taken on a Nikon TE300 microscope or a Nikon inverted Ti microscope with a Yokogawa spinning disk confocal system. Slides were then washed in PBS and stained with β-catenin Ab as described above.

CRC specimen collections and mutational analysis

A total of 301 paraffin-embedded CRC tissues were analyzed. KRAS mutations were determined on DNA extracted from the xenograft tumors and archived tissues by targeted pyrosequencing for codons 12 and 13 (23). Xenograft tumors were additionally tested for mutations in NRAS codons 12, 13, and 61, and BRAF codon 600 (24). Frequency data were analyzed using the χ² test. Statistical procedures applied SPSS version 19.0 (SPSS Inc.). Human subjects committees at the respective hospitals approved the study.

Results

Isolation of CRC cell populations with differing levels of WNT pathway activity

Caco2 and SW1222 human CRC cells carry classical APC mutations (25) and form well-differentiated glandular tumors in NOD/SCID mice, with heterogeneous intratumoral expression and distribution of β-catenin (Supplementary Fig. S1A and B), similar to observations in primary CRCs (5). To mark tumor cells showing high intrinsic WNT activity, we transduced these cell lines with a lentiviral vector carrying TOP-GFP, a WNT-pathway reporter in which multimerized TCF/LEF promoter elements drive expression of GFP (Fig. 1A). To test reporter specificity, we used FOP-GFP, a control vector with mutant TCF-binding sites (Supplementary Fig. S2A). Cells were expanded clonally to exclude the nontransduced population and then xenografted into NOD/SCID mice (Fig. 1B). These clones showed high GFP in all cultured cells (Supplementary Fig. S2B), whereas their xenografts showed differential GFP expression (Fig. 1C, Supplementary Fig. S2C), pointing to an environmental influence on WNT heterogeneity. In tumors expanded from Caco2TOP-GFP cells, the GFP signal colocalized with nuclear staining for β-catenin (Fig. 1C) and in SW1222TOP-GFP tumors, GFP and nuclear β-catenin largely overlapped (Supplementary Fig. S2C). Moreover, GFP expression marked tumor cells with active, dephospho–β-catenin (Supplementary Fig. S2D).

To mark tumor cells with differential WNT activity in primary CRCs, we first propagated fresh tumors as xenografts in mice, noting that they preserved their original morphology and displayed differential expression of nuclear β-catenin (Supplementary Fig. S1B and C). Because primary tumors have a heterogeneous composition, we preferred to avoid in vitro expansion of single transduced cells, which might select atypical clones. Instead we constructed a 2-color reporter, TOP-GFP,mC, which allows constitutive nuclear mCherry expression in infected cells and regulated GFP expression in response to WNT pathway activity (Fig. 1D, Supplementary Fig. S2E). Fluorescence microscopy revealed nuclear mCherry expression in transduced primary CRC cells and a subset of these cells expressed GFP (Fig. 1E). Thus, after excluding nontransduced, mCherry-negative tumor cells, GFP again marked rare tumor cells that showed nuclear β-catenin (Fig. 1F).

We isolated GFPhigh and GFPlow cell fractions by flow cytometric sorting of disaggregated xenografts from TOP-GFP– transplanted cell lines and TOP-GFP,mC–transplanted primary CRCs. The GFPhigh population showed significantly higher mRNA levels of known WNT target genes, including the intestinal stem cell marker LGR5 (Fig. 1G and H, Supplementary Fig. S3A). Gene expression profiles of GFPhigh and GFPlow cells from Caco2TOP-GFP revealed differential expression of 692 transcripts. Of these, 11 are annotated components of the WNT pathway and 9 of the 11 transcripts showed higher expression in the GFPhigh cell fraction (Supplementary Fig. S3B). Thus, TOP-GFP based constructs reliably marked a WNT-active subpopulation of CRC cells with nuclear β-catenin and allowed their isolation from bulk xenografts. However, the lesser enrichment for nuclear β-catenin and lower differential expression of WNT target genes among GFPhigh cells from SW1222TOP-GFP suggest that CRCs vary in the degree of heterogeneity in WNT activity.

Tumor cell fractions with different levels of WNT activity are equally tumorigenic

To characterize tumor cells with high and low WNT activity, we examined differential expression of all cell surface marker genes, as defined by Gene Ontology criteria, in GFPhigh and
GFPlow cells isolated from Caco2TOP-GFP xenografts. Among the 16 differentially expressed surface markers were several that are reported or suspected to mark tumorigenic CRC cells, including CD133 (PROM1), CD166 (ALCAM), and LGR5; expression of these transcripts was consistently higher in the GFPhigh than in the GFPlow cell fraction (Fig. 2A). mRNA expression profiles of TOP-GFP.mC–transduced GFPhigh and GFPlow primary tumor cells also showed increased levels of these candidate stem and progenitor cell markers (Fig. 2A). These results suggested the possibility that CRC cells with the highest WNT activity might harbor increased tumorigenic potential, as others report (16). To test this hypothesis, we injected limiting dilutions of GFPhigh and GFPlow colon cancer cells into both flanks of NOD/SCID mice and followed the appearance of tumors. Indeed, GFPhigh cells from Caco2TOP-GFP xenografts were more tumorigenic than the GFPlow cell fraction and the tumors grew faster (Fig. 2B, Supplementary Fig. S4B). Despite extensive testing on many animals, however, we did not observe such differences for cells isolated from SW1222TOP-GFP tumors or from 3 primary CRCs transduced with TOP-GFP.mC (Fig. 2B); one primary tumor manifested low tumorigenic potential in mice irrespective of cellular GFP.
expression levels. These data showed that CRC cells with high WNT activity and high expression of candidate cancer stem cell markers do not necessarily have an exclusive or enhanced capacity to spawn new tumors.

High WNT activity is associated with MAPK pathway activation in colon cancer cells

Recent data from zebrafish embryos suggest a role for MAPK signaling in nuclear accumulation of β-catenin in the presence of mutant APC (26). To investigate whether MAPK activity has a role in differential WNT activity in CRC cell subpopulations, we first compared the profile of transcripts that are altered in GFPhigh or GFPlow tumor cells to a canonical MAPK target gene signature (27). Of the 31 differentially expressed genes common to the two sets (Fig. 3A), 29 were expressed at higher levels in WNT-active, GFPhigh cells compared with GFPlow cells (P < 10<sup>−4</sup>, Fig. 3B); only 2 genes were expressed at lower levels, indicating activation of MAPK targets in the GFP high cell fraction. We then tested our xenograft sources for mutations most likely to affect MAPK signaling, in KRAS, BRAF, and NRAS. Both cell lines were wild type for all 3 genes but primary Tu1 carried the V600E mutation in BRAF and primary Tu3 had a G12A mutation in KRAS. Surprisingly, although MAPK activation is considered a global feature of CRCs carrying such mutations, the activity marker phospho-ERK appeared only in a fraction of the cells in every tumor source (Fig. 3C and data not shown). Importantly, immunostaining of Caco2 and primary colon cancer xenografts revealed colocalization of p-ERK and nuclear β-catenin (Fig. 3C). Thus, MAPK signaling is heterogeneous in CRC and increased in the tumor cell fraction with high WNT activity and nuclear accumulation of β-catenin.

To assess this association in clinical samples, we examined MAPK signaling and nuclear β-catenin accumulation in 301 primary CRCs with known KRAS mutation status. Similar to the xenografts, phospho-ERK immunostaining in 118 of these CRC specimens confirmed nonuniform MAPK signaling, irrespective of the underlying KRAS gene status (Supplementary Fig. S5A). We then scored nuclear β-catenin in tissue sections on a scale from 0 (no nuclear β-catenin) to 3 (most tumor cells showing strong nuclear β-catenin), hence classifying cases as β-catenin<sub>low</sub> (scale 0–1) or β-catenin<sub>high</sub> (scale 2–3, Fig. 3D), and observed that KRAS mutant tumors are significantly enriched for high nuclear β-catenin (Fig. 3E). Taken together, these data supported the idea that active KRAS might contribute to nuclear accumulation of β-catenin.

Figure 2. Lack of tumor-initiating capacity of WNT/GFPhigh tumor cell subpopulations despite enriched expression of suggested cancer stem cell markers. A, heat maps depicting differential expression of cell surface markers in GFPhigh and GFPlow cells isolated from Caco2TOP-GFP (left) and from TOP-GFP.mC–transduced primary tumor (P-Tu, right) xenografts. Columns represent samples and rows represent genes. Expression is represented in a pseudocolor scale (−3 to +3), with red denoting high and blue denoting low relative expression. B, frequencies of tumor formation upon subcutaneous injection of 10 to 100,000 flow-sorted GFPhigh and GFPlow tumor cells into NOD/SCID mice. Caco2TOP-GFP, SW1222TOP-GFP, and 3 independent TOP-GFP.mC–transduced primary colon cancer xenografts (P-Tu1–3) were tested, with at least 3 different tumor xenografts from each source. The fractions indicate numbers of tumors formed (numerator) per experimental replicate (denominator). The P value refers to a significant difference in tumor frequency between GFPhigh and GFPlow cells (χ<sup>2</sup> test). n.s., nonsignificant.
-catenin in CRC, in which both MAPK signaling and WNT activity show intratumor heterogeneity. These findings suggested roles for KRAS and MAPK signaling in differential WNT activity.

Functional relationship of MAPK and WNT pathway activities
To test whether MAPK pathway activation influences WNT pathway activity, we constructed a lentiviral vector to express...
constitutively active KRAS and, as a marker of cell infection, GFP (Fig. 4A). Increased phospho-ERK levels in transduced cells verified that introduction of this vector activates MAPK signaling, as expected (Fig. 4A). We infected CRC cell lines and primary tumors with low-titer lentivirus and grafted the cells in NOD/SCID mice to obtain tumors containing a mix of infected and uninfected tumor cells (Fig. 4A). Immunostaining of tumor sections revealed increased β-catenin levels and its nuclear localization in transduced, GFP⁺ tumor cells (Fig. 4B, Supplementary Fig. S5B). The levels of WNT target transcripts were also increased selectively in the transduced cell fractions (Supplementary Fig. S5C). Thus, forced activation of MAPK signaling through high levels of constitutively active KRAS leads to nuclear accumulation of β-catenin and increased WNT activity in CRC.

To test whether inhibition of MAPK signaling opposes β-catenin accumulation, we treated cultured CRC cells and mice bearing primary CRC xenografts with the epidermal growth factor receptor (EGFR) antibody cetuximab, which inhibits cellular MAPK activity (28). Treated tumors showed significantly fewer cells with nuclear β-catenin (Fig. 4C and D). Likewise, treatment of cultured Caco2TOP-GFP cells reduced expression of GFP and WNT target genes (Supplementary Fig. 5D). Moreover, primary tumor xenografts carrying the WNT reporter TOP-GFP.mC showed reduced GFP fluorescence and depletion of the GFP⁺ cell fraction (Fig. 4E and F). Thus, EGFR antibody-mediated blockade of MAPK signaling reduces WNT pathway activity in CRC cells. Surprisingly, these effects were evident despite the presence of a KRAS mutation in one primary tumor.

Discussion

APC or CTNNB1 mutations in nearly all CRCs are presumed to activate WNT signaling in all clonally derived tumor cells (29, 30). Heterogeneity in nuclear β-catenin levels in most CRCs and differential expression of WNT target genes, therefore, present a paradox and suggest that additional factors contribute to WNT pathway activity (6, 7). To isolate viable tumor cells showing differential WNT activity, we transduced xenografts of primary tumors and CRC cell lines with fluorescent reporters.
of canonical WNT activity (18). Although cultured CRC cells expressed GFP uniformly, all xenografts displayed highly heterogeneous GFP expression, similar to a recent study (16). Thus, the local environment or the 3-dimensional structure in xenografts seem necessary to reveal this latent heterogeneity. In tumor xenografts, nuclear β-catenin colocalized with high GFP expression as well as with enriched expression of WNT pathway components and WNT target genes in GFP<sup>high</sup> tumor cells. These data confirmed differential WNT pathway activity within CRCs and provided a reliable means to isolate cells with different levels of WNT activity. However, even though differentially expressed genes included the candidate human CRC stem cell markers CD133, CD44, and CD166 (11–13), and the intestinal stem cell marker LGR5 (31), WNT/GFP<sup>high</sup> cells from only 1 of the 5 tested sources showed a modest increase in tumor-initiating capacity. These data from a small number of primary CRC specimens indicate that high WNT activity does not signify particular tumorigenic potential in CRC and is not a reliable marker for tumor initiation in xenografts. Accordingly, they question the generality of a recent argument that high WNT activity is a distinguishing feature of CRC stem cells (16). The contrast between our findings and those of Vermeulen (16) mirror the conflicting results from different laboratories’ use of CD133 as a surface marker of tumor-initiating CRC cells (32). We suggest that the differing outcomes of such studies reflect highly variable genetic or phenotypic properties of tumors. Differences in experimental design, such as whether primary tumor cells were first expanded in spheroid cultures (16) or cultivated directly in xenografts, may also contribute to the discrepancy. Of course, it still unclear how accurately tumor xenografts model tumor-initiating cell subpopulations (33, 34).

Despite the lack of an obvious association with tumor initiation, heterogeneous WNT activity correlates with disease progression in CRC (5, 6, 26), adding to the importance of identifying the causes. Brabletz and colleagues and Vermeulen and colleagues have separately proposed that tumor cell stimulation by the microenvironment may modulate β-catenin accumulation and WNT pathway activity (6, 16), and studies in zebrafish embryos and a single CRC cell line recently implicated tumor cell MAPK signaling in the underlying mechanism (26). Reinforcing this idea, we observed colocalization of nuclear β-catenin and the MAPK pathway indicator phospho-ERK in cell line and primary tumor xenografts, and expression of MAPK target genes is enriched in highly WNT-active CRC cells. We also detected a statistical association between nuclear β-catenin and the presence of activating mutations in the MAPK pathway gene KRAS. Our data are consistent with the observation that intestinal tumors in <i>Kras<sup>G12V</sup>; Apc<sup>++/+</sup></i> mice have more cells with nuclear β-catenin than do their Apc<sup>−/−</sup> littermates (35). Notably both, <i>Kras</i> mutant and wild-type tumors showed heterogeneous MAPK activity, implying that signaling remains responsive to exogenous factors even when cells carry activating mutations. Although this observation begs an explanation for variable MAPK pathway activity among cells in the same tumor, our data begin to explain why MAPK and WNT pathway activities are high in the same cells.

<sup>KRAS</sup> mutations that activate MAPK signaling are especially common in selected cancers, including about 40% of CRCs (2), in which they occur early in the disease course, soon after <i>Apc</i> or <i>CTNNB1</i> mutations (36). <sup>KRAS</sup> mutations in the intestinal epithelium are oncogenic only when accompanied by deregulation of the WNT pathway (37). The full significance of this association and of the sequence of mutations is unclear and our data shed useful light. Forced expression of mutant KRAS in CRCs enhanced nuclear β-catenin accumulation and increased the levels of WNT target genes, whereas blocking the tyrosine kinase receptor EGFR, an activator of MAPK signaling (38), had the converse effects. Thus, MAPK signaling does not merely coincide with nuclear β-catenin but also regulates it. In line with these observations, insertional mutagenesis in <i>Apc<sup>fl</sup></i> mice recently uncovered 4 new candidate positive modifiers of canonical Wnt signaling (39) and one of these, EGF receptor kinase substrate 8, transduces EGF and RAS signals. Thus, modulation of canonical Wnt signaling through MAPK is a factor in colorectal tumorigenesis, and our study highlights this effect in tumor cell subpopulations. Phelps and colleagues recently proposed that KRAS and RAF1, but not MEK1, induce nuclear accumulation of β-catenin in APC-deficient cells (26). Further study is necessary to elucidate the detailed basis for this pathway cross-talk.

The fact that EGF and, perhaps, additional signals from the tumor microenvironment contribute to heterogeneous WNT activity in CRC also suggests new considerations for treatment of this disease. There are intensive ongoing efforts to design drugs that suppress WNT activity in CRC; these drugs may synergize with those that target MAPK signaling, such as cetuximab. Conversely, investigators recently described the use of transcriptionally active β-catenin to induce apoptosis in APC-deficient tumors (40). If growth factor signaling enhances WNT activity, then simultaneous targeting of growth factor pathways may downregulate the intended target and hence diminish the effects of WNT-directed therapy. Our observation that cetuximab reduced intratumoral heterogeneity of nuclear β-catenin also raises the possibility that the degree of heterogeneity in WNT pathway activity may help predict the therapeutic response to agents that target MAPK signaling. Thus, a fuller understanding of the interactions between WNT and MAPK signaling will better inform the design and interpretation of therapeutic trials.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

**Conception and design:** D. Horst and R.A. Shivdasani.

**Development of methodology:** D. Horst and R.A. Shivdasani.

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** D. Horst, J. Chen, T. Morikawa, S. Ogino, T. Kirchner, and R.A. Shivdasani.

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** D. Horst, J. Chen, S. Ogino, T. Kirchner, and R.A. Shivdasani.

**Writing, review, and/or revision of the manuscript:** D. Horst, S. Ogino, T. Kirchner, and R.A. Shivdasani.
Grant Support

The work was supported by a grant from the Harvard Stem Cell Institute (R.A. Shvidasani), a fellowship from the Deutsche Forschungsgemeinschaft (D. Horst), and grants R01 CA151993 (S. Ogino) and P50CA127003 from the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 28, 2011; revised December 28, 2011; accepted January 16, 2012; published OnlineFirst February 8, 2012.

References


Differential WNT Activity in Colorectal Cancer Confers Limited Tumorigenic Potential and Is Regulated by MAPK Signaling

David Horst, Justina Chen, Teppei Morikawa, et al.

Cancer Res  Published OnlineFirst February 8, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-11-3222

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2012/02/08/0008-5472.CAN-11-3222.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.